US Bancorp
CRVS icon

US Bancorp’s Corvus Pharmaceuticals CRVS Stock Holding History

US Bancorp’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.48K Sell
166
-937
-85% -$13K ﹤0.01% 3824
2026
Q1 		$16.1K Buy
+1,103
New +$17.6K ﹤0.01% 3193
2022
Q2 		– Sell
-5,153
Closed -$8K – 4097
2022
Q1 		$8K Buy
+5,153
New +$9.43K ﹤0.01% 3443

Other funds holding CRVS

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

US Bancorp's CRVS Position: Q2 2026 in Review

US Bancorp reduced its Corvus Pharmaceuticals (CRVS) stake by 85% in Q2 2026, selling an estimated $13K and leaving 166 shares worth $2.48K. The position accounts for ﹤0.01% of the portfolio, ranked #3824.

US Bancorp first reported a position in CRVS in Q1 2022 and has held it in 3 quarters since. The position peaked at $16.1K in Q1 2026. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • US Bancorp held 166 shares of Corvus Pharmaceuticals worth $2.48K as of Q2 2026.
  • US Bancorp sold 937 Corvus Pharmaceuticals shares in Q2 2026, an estimated $13K.
  • Corvus Pharmaceuticals made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3824 holding.
  • US Bancorp first reported a position in Corvus Pharmaceuticals in Q1 2022 and has held it in 3 quarters since.
  • US Bancorp's Corvus Pharmaceuticals position peaked at $16.1K in Q1 2026.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.